Nucleoside analogs represent the most closely studied family of antiviral agents. Of these, zidovudine (3'-azido-3'-deoxythymidine [AZT]) has emerged as the drug of choice for combatting human immunodeficiency virus type 1 (HIV-1) infection. There is good evidence that AZT therapy can delay although not necessarily stop the onset of AIDS, the late and fatal outcome of infection by HIV-1 (2, 3, 12, 14) . AZT is phosphorylated upon entering the cell and can then act as a strong inhibitor of reverse transcription, a key step in the retroviral life cycle (4, 22) . In addition, there is a demonstrated potential for emergence of drug-resistant virus strains in patients who have received AZT over long periods (9, 16, 19) . Several other nucleoside analogs, such as 2',3'-dideoxyinosine and 2',3'-dideoxycytidine, have also been shown to possess significant anti-HIV activity in vitro (6, 8, 13) ; both 2',3'-dideoxyinosine and 2',3'-dideoxycytidine have been studied in clinical trials (21) . Toxic side effects have been dose-limiting features with each of these agents.
The present study describes a novel nucleoside analog, 2'-deoxy-3'-thiacytidine (BCH-189), in which the 3' carbon in the ribose ring of 2'-deoxycytidine has been replaced by a sulfur atom (Fig. 1 ). We now demonstrate that this new compound has potent in vitro anti-HIV-1 activity in both T-lymphoid and monocytoid cell lines, as well as in primary cultures of human peripheral lymphocytes. Moreover, BCH-189 is less toxic than AZT in tissue culture, which may make it a promising candidate drug for the treatment of HIV-1-associated disease.
( Human peripheral blood mononuclear cells (PBMCs) were obtained by Ficoll-Hypaque (Pharmacia Labs, Montreal, Canada) density gradient centrifugation of blood collected from male HIV-1-seronegative volunteers. The PBMCs were stimulated with 0.1% phytohemagglutinin in supplemented RPMI 1640 medium and subsequently maintained in the presence of5% recombinant interleukin-2 (Boehringer-Mannheim, Montreal, Canada) for 72 h prior to infection, as previously described (5, 16, 17) .
HIV-1 strains and infection. The HIV-IIIB isolate of HIV-1 was kindly supplied by R. C. Gallo, National Institutes of Health, Bethesda, Md. UHC-1 virus was derived from a cell clone of U937 cells that had been chronically infected with HIV-IIIB (1) and was employed because of its high infectiousness for U937 cells. We also studied two pairs of AZT-susceptible and -resistant clinical isolates of HIV-1, obtained from infected asymptomatic subjects both prior to and following initiation of AZT therapy, as described previously (16) . Both of the AZT-resistant viruses studied were mutated at amino acid positions 70 and 215 of viral reverse transcriptase (RT), as determined by polymerase chain reaction using published primer pairs and techniques (10) . All viruses were pelleted by ultracentrifugation from clarified culture fluids. Infectivity of each isolate was quantified by end-point titration in MT-4 cells, and virus stocks were kept frozen at -70°C until used. All cells were infected at a Susceptibility testing. To determine the levels of inhibition of HIV-1 replication by BCH-189, we infected MT-4 cell cultures (pretreated for 3 h with various concentrations of the drug) with a panel of five different isolates of HIV-1. RT activity in the culture fluids was measured, as previously described (11), at 5 days postinfection. AZT was tested in an identical fashion in parallel cultures. The results were expressed as the 50% inhibitory dose (ID50), as measured by determinations of viral RT levels in culture fluids. All studies were carried out with three replicate samples, and the results were analyzed by Student's t test when applicable. Cell proliferation in untreated controls was not impaired in these studies.
The viral p24 antigen (Ag) present in culture fluids was quantitated by using a commercially available kit (Abbott Laboratories, North Chicago, Ill.) according to the manufacturer's instructions. All assays were performed with three replicate samples.
Toxicity testing. For toxicity testing, three replicate cul- For MT-4 cells, the CCID50 of BCH-189 was 405 ,uM, about 10-fold greater than that of AZT (37.6 ,uM) (Fig. 2) . In BCH-189 suppressed HIV-1 production for more than 45 days, as determined by production of viral RT activity.
Similar results were obtained by p24 Ag capture assay. In contrast, the use of a similar concentration of AZT was he values of their respective therapeutic indices somewhat less effective in these cells. Single-pulse pretreat-)50, a standard measure of drug efficacy), as ment with either drug was largely ineffective (Fig. 4) .
with the means obtained from -d with 10 puM BCH-189 from 4 h preinfection to Finally, we assessed the ability of BCH-189 to inhibit ifection. A direct relationship between the time of HIV-1 replication in freshly isolated primary cultures of iistration and the magnitude of inhibition of RT PBMCs. Replicate cultures were infected with either the the cell culture supernatants was shown: the AZT-susceptible (from patient B) or AZT-resistant (from onset of treatment, the more complete the inhibipatient B) HIV-1 strain and then treated with either AZT (1 V-1 production (Fig. 3A) .
,uM) or BCH-189 (10 ,uM), starting at various times postin--mine whether the duration of BCH-189 maintefection. Both viral RT activity and p24 Ag levels were he tissue culture medium influenced the level of measured in culture fluids after 7 days. (10 ,uM) at the end of the adsorption period. Medium changes were carried out twice weekly and either included or excluded fresh drug according to the following schedule: BCH-189 (10 ,M) was included at each medium change (A); fresh drug added after 7 days and at subsequent weekly intervals (A); or fresh drug added after 14 days and at 14-day intervals (D). O, no-drug control.
when drug treatment started as late as 10 h postinfection. In contrast, AZT was unable to block the ultimate replication of either virus (Table 2) .
DISCUSSION
We have shown that BCH-189 possesses lower anti-HIV activity in MT-4 cells than AZT; in contrast, BCH-189 appeared to be a more effective antiviral agent than AZT in both cultures of U937 cells and PBMCs. The growth of each of five different HIV-1 isolates was inhibited by BCH-189, and we confirmed that two known AZT-resistant HIV-1 strains did not exhibit cross-resistance to it. We showed that BCH-189 could effect a total suppression of HIV-1 production in U937 cells for a period of almost 50 days, something that could not be achieved with similar doses of AZT. We have also demonstrated that the time of onset of exposure to BCH-189 and the duration of such exposure can each play an important role in limiting HIV-1 replication.
In terms of toxicity, the 50% lethal dose of BCH-189 in MT-4 cells is more than 10 times higher than that of AZT. 
